Written Question·Department of Health and Social Care·UIN 83209
Abiraterone
Tabled: 17 October 2025
Answered: 26 November 2025
Question
Danny Beales
Labour — Uxbridge and South Ruislip
To ask the Secretary of State for Health and Social Care, for what reason NHS England has not approved abiraterone for use in high-risk, non-metastatic prostate cancer.
Answer
Dr Zubir AhmedAbiraterone is licensed by the Medicines and Healthcare products Regulatory Agency for use in the treatment of high-risk hormone-sensitive metastatic prostate cancer. The National Institute for Health and Care Excellence (NICE) has published final draft g...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 83209) →